Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)-Reference-Cited by-同舟云学术

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Published:2022-03-01 Issue:3 Volume:193 Page:555-564
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Geyer Charles E.^ORCID,Bandos Hanna,Rastogi Priya,Jacobs Samuel A.,Robidoux André,Fehrenbacher Louis,Ward Patrick J.,Polikoff Jonathan,Brufsky Adam M.,Provencher Louise,Paterson Alexander H. G.,Hamm John T.,Carolla Robert L.,Baez-Diaz Luis,Julian Thomas B.,Swain Sandra M.,Mamounas Eleftherios P.,Wolmark Norman

Funder

National Institutes of Health

Pharmacia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06417-y.pdf

Reference14 articles.

1. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8(9):1483–1496

2. Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19(4):931–942. https://doi.org/10.1200/JCO.2001.19.4.931